Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...

Nearly one in 10 American adults now report having been diagnosed with cancer at some point in their lives—a notable jump from 7% in 2008-2009, according to the latest data from Gallup. Gallup says ...

In the summer of 2020, while the virus raged and my marriage folded in and collapsed in slow motion upon itself, I decided that I would become infertile. My husband sat next to me in the waiting room ...

COVID-19 mRNA vaccines create enough of an immunity boost to extend survival in certain types of lung and skin cancers, an analysis of more than 1,000 patient files showed. The scientific journal ...

A common vaccine could help to fight cancer, a new study suggests. For cancer patients undergoing immunotherapy, researchers found that receiving the mRNA COVID-19 vaccine within about 100 days of ...

Certain individuals with cancer were significantly more likely to survive if they received a COVID-19 mRNA vaccine, researchers at the University of Texas MD Anderson Cancer Center reported. This ...

An objective response rate of 50.5% was observed with raludotatug deruxtecan across all dose levels in these patients in the phase 2 part of REJOICE-Ovarian01 Phase 3 part of REJOICE-Ovarian01 to ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically ...

The Florence + the Machine singer was in the early weeks of pregnancy when she experienced pain and bleeding; she didn't know her fallopian tube had ruptured Joy Malone/Getty Florence Welch said she ...

Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...